Triple Negative Breast Cancer Clinical Trials

68 studies are recruiting for triple negative breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

   This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale Cancer Center Clinical Trials Office, New Haven, Connecticut

   Locations

   6 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07340541 on ClinicalTrials.gov

2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

   This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and d…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Infirmary Cancer Care ( Site 0001), Mobile, Alabama

   Locations

   311 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06393374 on ClinicalTrials.gov

3. Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

   This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ellison Institute of Technology (EITM), Los Angeles, California

   Locations

   3 in total

   Run by

   Providence Health & Services

   See if you can join NCT06353997 on ClinicalTrials.gov

4. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Denver, Aurora, Colorado

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

5. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

6. Study of Screening Brain MRIs in Stage IV Breast Cancer

   The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Morton Plant Mease- Baycare, Clearwater, Florida

   Locations

   2 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT05115474 on ClinicalTrials.gov

7. A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

   Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06246968 on ClinicalTrials.gov

8. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

   The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Alabama Oncology, Birmingham, Alabama

   Locations

   372 in total

   Run by

   Gilead Sciences

   See if you can join NCT05633654 on ClinicalTrials.gov

9. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

10. Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

    This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Emory University, Atlanta, Georgia

    Locations

    7 in total

    Run by

    Kathy Miller

    See if you can join NCT05846789 on ClinicalTrials.gov

11. PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

    Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with compl…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Locations

    2 in total

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06245889 on ClinicalTrials.gov

12. PRE-ISPY Phase I/II Oncology Platform Program

    PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

    Locations

    10 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT05868226 on ClinicalTrials.gov

13. ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

    This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory University Winship Cancer Institute, Atlanta, Georgia

    Locations

    2 in total

    Run by

    ProDa BioTech, LLC

    See if you can join NCT06460298 on ClinicalTrials.gov

14. Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

    A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation, including an observational arm to describe response in patients who are not …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT04677816 on ClinicalTrials.gov

15. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START-San Antonio, San Antonio, Texas

    Locations

    54 in total

    Run by

    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

16. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

17. Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

    This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of immunotherapy. This is a parallel imaging study to current treatment strategies …

    Stage

    EARLY_Phase 1

    Ages

    18 to 75

    Site

    UAB, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04861077 on ClinicalTrials.gov

18. Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

    This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Andrew Hantel, MD

    See if you can join NCT07341867 on ClinicalTrials.gov

19. A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

    The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.

    Stage

    Phase 2

    Ages

    70 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07768436 on ClinicalTrials.gov

20. Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

    The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes i…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford University, Stanford, California

    Run by

    Stanford University

    See if you can join NCT04768426 on ClinicalTrials.gov

21. Breast Cancer PSMA PET

    The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSM…

    Stage

    EARLY_Phase 1

    Ages

    18 to 90

    Site

    University of Iowa Healthcare, Iowa City, Iowa

    Run by

    Ahmad Shariftabrizi

    See if you can join NCT06586047 on ClinicalTrials.gov

22. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USOR HonorHealth, Phoenix, Arizona

    Locations

    66 in total

    Run by

    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

23. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    Uni of Alabama at Birmingham, Birmingham, Alabama

    Locations

    29 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06562192 on ClinicalTrials.gov

24. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists - Lake Nona, Orlando, Florida

    Locations

    10 in total

    Run by

    Compass Therapeutics

    See if you can join NCT06150664 on ClinicalTrials.gov

25. Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

    This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06347068 on ClinicalTrials.gov